FDA clears Servier and Pfizer for clinical development of UCART19 for acute lymphoblastic leukemia
The UCART19 lymphoblastic leukemia drug jointly developed by Servier and Pfizer has been given the FDA clearance for its clinical development for lymphoblastic leukemia treatment.
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with the clinical development of UCART19, an innovative gene-edited therapy for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Groundbreaking Gene-Edited Therapy UCART19, a chimeric antigen receptor (CAR) T-cell therapy, targets CD19-expressing hematological malignancies […]